NCT06346067 2026-02-27A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)Erasca, Inc.Phase 3 Active not recruiting78 enrolled